Compare Becton Dickinson and Co (BDX) vs Wix.Com Ltd (WIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs Wix.Com Ltd — how do they compare? Becton Dickinson and Co trades at $154.29 (market cap $41.51B), while Wix.Com Ltd trades at $52.77 (market cap $2.21B). The key difference: Becton Dickinson and Co is far larger — about 18.8× Wix.Com Ltd's market cap, and Becton Dickinson and Co pays a 2.79% dividend while Wix.Com Ltd pays none. Which is the better fit depends on your goals.
| BDX | WIX | |
|---|---|---|
Market Cap | $41.51B | $2.21B |
Sector | Health | Technology |
52-Week High | $185.39 | $184.24 |
52-Week Low | $135.49 | $40.43 |
Enterprise Value | $57.97B | $1.77B |
Dividend Yield | 2.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX trades at $153.83, up 1.24% today, with technical indicators showing a neutral to bullish bias. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $2.90 exceeding expectations. Revenue growth remains steady, reaching $21.84B in 2025, though net margins have compressed to 5.12%. Recent news highlights BDX's innovation in medical technology and positive analyst sentiment.
The outlook for BDX appears balanced. Upside potential exists from continued earnings beats and strategic positioning in growing healthcare segments like GLP-1 drug support equipment. However, risks include margin pressure, elevated debt levels, and cautious hospital spending. The consensus price target of $173.40 suggests moderate upside from current levels.
Wix trades at $52.41, up 4.53% today, with a bullish technical signal from moving averages but overbought RSI readings. Revenue grew to $1.99B in 2025, though net income fell to $50.65M, and the stock carries a high P/E of 62.84. Recent news highlights AI-related volatility and a partnership with Elavon to enhance small business payments.
The outlook is mixed: strong analyst consensus (67.5% buy ratings) and a $83.13 price target suggest upside, but risks include legal investigations, expense spikes, and negative shareholder equity. Earnings misses in Q1 2026 and high valuation metrics warrant caution despite growth potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About Wix.Com Ltd
Wix.com Ltd is a cloud-based development platform provider for millions of registered users worldwide. The company is engaged in web development and management that provides an easy-to-use powerful cloud-based platform of products through a freemium model. Its core products consist of three web editors: the Wix Editor, intended for users with basic technological skills, Wix ADI, intended for novice users and Corvid, intended for more tech-savvy users. The company's web development technology is built based on HTML5 and offers HTML5 compatible capabilities, web design and layout tools, domain hosting, and other marketing and workflow management applications and services. The geographic segments include North America, Europe, Latin America, Asia and others.
Read more on WIX →
